多西他赛联合卡铂治疗老年晚期非小细胞肺癌临床观察

目的观察多西他赛（docetaxel）联合卡铂（carboplatin）治疗老年晚期非小细胞肺癌的临床疗效及毒副反应。方法老年晚期非小细胞肺癌患者共40例，多西他赛用量75mg/m^2，每天静脉滴注，同时配伍卡铂AUC=5mg·ml^-1·min^-1，每天静脉滴注。21～28d为1个疗程，每例患者至少接受2个疗程的治疗。结果40例患者均可评价疗效，无完全缓解病例（CR），15例获部分缓解（PR），20例稳定（SD），5例疾病进展（PD），总有效率为37．5％（15／40），其中位疾病进展时间为4．5个月，中位生存时间10．2个月（3～20个月），1年生存率为45．1％。毒性反应主要有骨髓抑制、恶心、呕吐和腹泻以及白细胞下降导致的发热等。但患者多为Ⅰ、Ⅱ度反应，耐受良好。结论多西他赛联合卡铂是一种对老年晚期非小细胞癌有效的治疗方法，毒性反应轻，临床使用安全。

Clinical study of docetaxed combination with carboplatin as the therapy in advanced senium later year non-small cell lung cancer

Objective To evaluate the clinical response rate and toxic reaction of docetaxel combination with carboplatin in the therapy of advanced senium non-small cell lung cancer （ NSCLC ）. Methods A total of 40 chemotherapy naive patients with stage ⅢB or Ⅳ NSCLC were enrolled in this study. Docetaxel was given at a dose of 75 mg/m2 over an 1 hour iv. Infusion every day. Carboplatin dosed to an area under the time-concentration curve （AUC） of 5 mg·ml^-1·min^-1 was administered iv. every day. The chemotherapy was repeated every 21 - 28 days. Each patient was given at least 2 cycles. Results The response rate of all the patients were evaluated. There were 15 PR, 20 SD and 5 PD in the group. The overall response rate was 37.5% （15/40）. Median time to progression （TTP） was 4. 5 months. Median survival duration was 10. 2 months （3-20 months）, 1 year survival rate was 45.1%. The major toxicity included neutropenia, vomiting and diarrhea, impaired liver function, and febrile neutropenia. The severity of these side effects was grade Ⅰ-Ⅱ and well tolerated. Conclusion Docetaxel combination with carboplatin is effective . in the treatment of advanced non-small cell lung cancer with moderate side effect and safety in the clinical practice.